alpha-methyltyrosine methyl ester has been researched along with Parkinson Disease in 2 studies
alpha-methyltyrosine methyl ester: RN given refers to parent cpd
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, A | 1 |
| Pavlova, E | 1 |
| Kolacheva, A | 1 |
| Bogdanov, V | 1 |
| Dilmukhametova, L | 1 |
| Blokhin, V | 1 |
| Valuev, L | 1 |
| Valuev, I | 1 |
| Gorshkova, M | 1 |
| Ugrumov, M | 1 |
| Klockgether, T | 1 |
| Turski, L | 1 |
2 other studies available for alpha-methyltyrosine methyl ester and Parkinson Disease
| Article | Year |
|---|---|
Development of early diagnosis of Parkinson's disease on animal models based on the intranasal administration of α-methyl-p-tyrosine methyl ester in a gel system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2022 |
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
Topics: Animals; Dizocilpine Maleate; Drug Synergism; Electromyography; Levodopa; Male; Methyltyrosines; Mot | 1990 |